HHS Office of Inspector General renews recommendation that Medicare exclude prices for self-administered versions of drugs reimbursed under Part B in report focused on overpayments for two autoimmune treatments.
Higher Payments Reflect Prices Of Self-Administered Forms Of Treatment
Medicare Part B spending for Bristol-Myers Squibb Company’s Orencia and UCB S.A.’s Cimzia during 2017 and 2018 was nearly $500m higher than it should have been because of the way average sales prices for the two drugs was calculated, the Health and Human Services Department Office of Inspector General concluded in a report released 8 July.
